Governed by UAMS Medical Policies and Procedures MS.4.35
Medications NOT released until approval granted by Antimicrobial Stewardship or Infectious Diseases consult:
- Aztreonam/avibactam (Emblaveo)
- Cefiderocol (Fetroja)
- Ceftaroline (Teflaro)
- Ceftazidime/avibactam (Avycaz)
- Ceftolozane/tazobactam (Zerbaxa)
- Cidofovir (Vistide)
- Colistin (Colymicin)
- Cytogam (CMV IVIG)
- Dalbavancin (Dalvance)
- Daptomycin (Cubicin)* (excluding ED/CDU and Cancer Institute)
- Eravacycline (Xerava)
- Ertapenem (Invanz)
- Foscarnet (Foscavir)
- Imipenem/cilastatin (Primaxin)
- Liposomal Amphotericin B (Ambisome)
- Meropenem (Merrem)* (excluding ICUs and Cancer Services)
- Meropenem/vaborbactam (Vabomere)
- Minocycline (IV only) (Minocin)
- Oritavancin (Orbactiv)
- Quinupristin/dalfopristin (Synercid)
- Rezafungin (Rezzayo)* (for outpatient use only)
- Sulbactam/durlobactam (Xacduro)
- Tigecycline (Tygacil)
- Voriconazole (IV only) (Vfend)
Non-formulary agents not included in this list are also subject to restriction.